What has pancreatic cancer research established? Published randomized trials show measurable progress in specific patient populations, while early-detection studies offer promising but more limited evidence. In the France–Canada PRODIGE 24/CCTG PA6 trial, the original published analysis found median overall survival of 54.4 months with a modified multi-agent chemotherapy regimen versus 35.0 months with its comparator after surgery. The New England Journal of Medicine published that result in 2018; it does not represent the expected survival of every person with pancreatic cancer. [1]
This educational overview reviews nine findings and clarifies which conclusions are supported by randomized trials, high-risk surveillance cohorts, or early laboratory work. The October 29 publication date precedes Pancreatic Cancer Awareness Month in November; the World Pancreatic Cancer Coalition also identifies November 19, 2026, as World Pancreatic Cancer Day. [9] This is a research summary, not individual medical or dosing guidance.
Table of contents
- Why pancreatic cancer research needs precise definitions
- Finding 1: Disease stage changes the question
- Finding 2: The Canadian-participating PRODIGE 24 trial
- Finding 3: Five-year follow-up matters
- Finding 4: NAPOLI 3 evaluated metastatic disease
- Finding 5: Biomarkers can define a smaller study population
- Finding 6: PREOPANC studied treatment sequence
- Finding 7: A021501 tested a difficult comparison
- Finding 8: CAPS offers a qualified early-detection signal
- Finding 9: Laboratory promise still needs clinical proof
- Side-by-side evidence table
- Where the next research questions lie
- Frequently asked questions
- References
Why pancreatic cancer research needs precise definitions
The term pancreatic cancer research describes a broad scientific field rather than one disease population or one intervention. Most of the landmark treatment trials discussed in this article involve pancreatic ductal adenocarcinoma (PDAC), the major exocrine cancer subtype. Pancreatic neuroendocrine tumours are biologically different and should not be assumed to share the same treatment-trial results.
In pancreatic cancer research, investigators also distinguish disease that has been surgically removed, disease considered resectable before an operation, borderline-resectable disease, locally advanced disease, and cancer that has spread to distant organs. Each category can generate different questions, comparators, and outcomes. A large result in one setting may have little direct meaning in another.
Responsible pancreatic cancer research reporting therefore names the patient population before presenting a survival number. It differentiates overall survival from progression-free survival, identifies whether an analysis was randomized or observational, and notes when data were collected. An outcome estimate is not a personal prognosis.
Nine research lessons at a glance
| Question | Evidence-based answer | Main study or evidence source |
|---|---|---|
| Does stage change interpretation? | Yes; eligibility defines what a result can mean | Trial protocols and disease classification |
| Can postoperative regimens differ? | A randomized France–Canada trial showed a substantial survival difference | PRODIGE 24/CCTG PA6 |
| Does longer observation add information? | Yes; updated five-year outcomes tested durability | PRODIGE 24 follow-up |
| Are metastatic comparisons measurable? | NAPOLI 3 reported different median survival estimates | NAPOLI 3 |
| Are all patients molecularly alike? | No; POLO tested a defined inherited mutation subgroup | POLO |
| Can treatment sequence influence outcomes? | PREOPANC tested a preoperative versus upfront-surgery strategy | PREOPANC |
| Does adding a modality always help? | A021501 did not support a blanket assumption | Alliance A021501 |
| Is earlier detection established for everyone? | CAPS surveillance is promising in selected high-risk cohorts | CAPS1–5 |
| Can a cell-line finding prove a human benefit? | No; translational studies require clinical verification | Research-methods principles |
Finding 1: Disease stage changes the question
Pancreatic cancer can be investigated at multiple points along a disease course. Trials after complete surgical removal examine recurrence and survival among people eligible for surgery. Studies of metastatic PDAC involve a different population. Preoperative trials investigate whether the order or combination of modalities changes outcomes among people selected for a possible operation.
For pancreatic cancer research, this segmentation is not a bureaucratic detail. People eligible for surgery often differ substantially from those enrolled in metastatic-disease studies. Comparing their median survival estimates directly would confuse patient selection with intervention effects. The valid comparison is generally the one defined within a study’s randomized groups.
Understanding three commonly reported endpoints
- Overall survival (OS): Time from a specified starting point until death from any cause.
- Progression-free survival (PFS): Time until a defined progression event or death, according to trial rules.
- Disease-free survival (DFS): Time without a defined recurrence or event after an initial disease-control point, often following surgery.
Within pancreatic cancer research, these endpoints should not be treated as synonyms. A trial may find a difference in progression-free survival without demonstrating a difference in overall survival. Similarly, a change in imaging-assessed tumour size may be scientifically valuable but cannot independently establish a survival advantage.
Good pancreatic cancer research communication includes trial dates, analysed populations, statistical uncertainty, and both benefits and harms. It can describe investigated clinical strategies without providing individual instructions. The purpose here is to interpret what was learned, not to select care for a particular person.
Finding 2: The Canadian-participating PRODIGE 24 trial
For pancreatic cancer research, PRODIGE 24/CCTG PA6 is especially important to a Canadian scientific audience because it involved the Canadian Cancer Trials Group alongside French investigators. The phase 3 randomized trial took place at 77 hospitals in France and Canada and studied people after resection of PDAC. Its initial findings were published by Conroy and colleagues in the New England Journal of Medicine in 2018. [1]
In this pancreatic cancer research report, median overall survival was 54.4 months in the modified FOLFIRINOX group versus 35.0 months in the gemcitabine group. The reported stratified hazard ratio for death was 0.64, with a 95% confidence interval of 0.48–0.86. Disease-free survival also differed, reflecting the trial’s specified postoperative population and follow-up. [1]
For pancreatic cancer research, the trial demonstrates how a controlled comparison can move beyond biological plausibility. Random assignment, defined eligibility, endpoint measurement, and statistical analysis allow researchers to assess differences between the interventions in the studied population.
The essential interpretation limit
The pancreatic cancer research survival estimates are medians from groups of participants after surgery. They are not survival guarantees, not estimates for all pancreatic tumours, and not a basis for self-directed use of any agent. Trial regimens have substantial risk and complex clinical eligibility considerations that this educational article does not attempt to operationalize.
Canadian involvement also does not make the findings uniquely applicable to every region of Canada. Pancreatic cancer research must still investigate whether trial populations represent diverse communities and how specialist services and outcomes vary across care settings.
Finding 3: Five-year follow-up matters
A pancreatic cancer research updated analysis of PRODIGE 24/CCTG PA6, published by Conroy and colleagues in JAMA Oncology in 2022, reported longer-term findings in 493 randomized participants. Its mature estimates differed slightly from the original report because additional outcomes accumulated during follow-up. [2]
The later pancreatic cancer research analysis reported median overall survival of 53.5 months versus 35.5 months, with five-year overall survival estimates of 43.2% and 31.4%. Median disease-free survival was 21.4 months versus 12.8 months. These figures are from the updated study, not a separate independent trial. [2]
This distinction is important for pancreatic cancer research. A 2018 report and a 2022 follow-up can both be accurate even if the medians differ, because survival estimates change as more participants reach endpoints and follow-up becomes longer. Authors must distinguish initial from updated estimates rather than presenting them as contradictory discoveries.
Why time horizon affects interpretation
In pancreatic cancer research, early results may be influenced by incomplete follow-up. Later analyses permit researchers to investigate durability, delayed events, and longer-term patterns. But repeated publications do not magically increase the original number of randomized patients or create independent replication.
Pancreatic cancer research improves when readers can identify whether a new article describes a new study, a pooled analysis, or a later evaluation of an existing cohort. Each provides different information about confidence and generalizability.
Finding 4: NAPOLI 3 evaluated metastatic disease
The pancreatic cancer research NAPOLI 3 randomized phase 3 trial, reported by Wainberg and colleagues in The Lancet in 2023, studied previously untreated metastatic PDAC. It compared the multi-agent NALIRIFOX regimen with nab-paclitaxel plus gemcitabine and enrolled 770 participants across international centres. [3]
In this pancreatic cancer research trial, the median overall survival was 11.1 months in the NALIRIFOX group versus 9.2 months in the comparator group. The reported hazard ratio was 0.83, with a 95% confidence interval of 0.70–0.99 and p = 0.036. These are trial-level outcomes in a defined metastatic population. [3]
For pancreatic cancer research, NAPOLI 3 demonstrates why headline numbers should always preserve their setting. A median from metastatic disease must not be casually compared against the postoperative survival median from PRODIGE 24 as if the trial groups began in comparable circumstances.
Benefits, trade-offs, and missing simplifications
Pancreatic cancer research trials generally assess safety and tolerability as well as efficacy. The more complex an intervention, the more important it becomes to inspect the full adverse-event profile and study exclusions. A favourable survival comparison alone is not a complete description of a regimen’s impact.
Pancreatic cancer research is strongest when investigators publish both efficacy and harms and when later work examines patient-reported outcomes and representation. Readers should be cautious of claims that describe a survival difference without naming the control arm or measured follow-up.
Finding 5: Biomarkers can define a smaller study population
The pancreatic cancer research POLO randomized, double-blind, placebo-controlled phase 3 trial, published by Golan and colleagues in the New England Journal of Medicine in 2019, studied a specific population: people with metastatic pancreatic cancer, an inherited BRCA1 or BRCA2 mutation, and disease that had not progressed after a specified prior clinical treatment context. [4]
This pancreatic cancer research trial enrolled 154 randomized participants and reported median progression-free survival of 7.4 months with investigational maintenance olaparib versus 3.8 months with placebo. Its primary conclusion concerned progression-free survival in this narrowly defined group, not effectiveness across all pancreatic cancers. [4]
The subsequent published overall-survival analysis did not establish a statistically significant overall-survival advantage. This illustrates a central pancreatic cancer research distinction: a positive PFS endpoint does not automatically imply a demonstrated OS benefit. The endpoints are related but not equivalent. [5]
What precision oncology actually means
In pancreatic cancer research, the phrase precision oncology refers to using tumour or inherited biological characteristics to define clinically meaningful subgroups or investigate particular mechanisms. It does not mean that every molecular marker already predicts a beneficial intervention. The marker must be analytically measured, clinically interpreted, and validated in appropriately designed studies.
For pancreatic cancer research, the POLO population shows why an inherited mutation can be a legitimate eligibility criterion in a trial. It does not justify assuming that all pancreatic tumours contain that mutation or that every experimental mechanism works in the same way for everyone.
Finding 6: PREOPANC studied treatment sequence
The pancreatic cancer research Dutch randomized PREOPANC trial evaluated a neoadjuvant chemoradiotherapy strategy against upfront surgery among people with resectable or borderline-resectable pancreatic cancer. The long-term results, published in the Journal of Clinical Oncology in 2022, involved 246 randomized participants. [6]
For pancreatic cancer research, the long-term report found a five-year overall-survival estimate of 20.5% in the neoadjuvant group versus 6.5% in the upfront-surgery group. Median overall survival was 15.7 months versus 14.3 months. The investigators reported a hazard ratio of 0.73 for overall survival, with a 95% confidence interval of 0.56–0.96. [6]
For pancreatic cancer research, the different sizes of the median and five-year comparisons are a reminder that one summary statistic does not capture the entire survival distribution. The trial also investigated a particular modality, treatment sequence, and era of care; it is not a universal verdict about every preoperative strategy.
The importance of the comparator
In pancreatic cancer research, an intervention can look promising in a single-arm cohort yet perform differently when a control group is included. Randomized comparisons help test whether a strategy improves outcomes beyond those expected under a contemporary alternative.
Pancreatic cancer research cannot be reduced to the slogan that earlier treatment is always better. Researchers must determine the clinical scenario, what was compared, which participants were eligible, and how complete follow-up was before interpreting the observed difference.
Finding 7: A021501 tested a difficult comparison
The pancreatic cancer research Alliance A021501 phase 2 randomized trial, published in JAMA Oncology in 2022, examined two preoperative approaches among people with borderline-resectable PDAC. It enrolled 126 participants and evaluated a systemic-therapy strategy against a strategy adding hypofractionated radiotherapy. [7]
For pancreatic cancer research, the published 18-month overall-survival estimates were 66.7% in one arm and 47.3% in the other. Importantly, the trial was designed with arm-specific comparisons against a historical benchmark and was not a definitive head-to-head superiority trial powered to prove a difference between the arms. [7]
That statistical feature is essential to pancreatic cancer research interpretation. Putting two numbers beside each other can invite a causal claim stronger than the design supports. The investigators’ own hypothesis structure, sample size, confidence intervals, and stopping decisions must determine what can reasonably be concluded.
More treatment is not automatically better
The pancreatic cancer research A021501 results caution against assuming that adding another modality guarantees a better outcome. Interventions can have burdens, affect the ability to complete subsequent procedures, and change the study population that ultimately reaches later endpoints.
For pancreatic cancer research, the appropriate lesson is methodological: combinations must be tested, not merely presumed helpful because their individual components have plausible mechanisms. Early-phase comparative results guide future questions while retaining their design limitations.
Finding 8: CAPS offers a qualified early-detection signal
Pancreatic cancer research teams would like to identify pancreatic malignancies at stages when disease control may be more achievable. Yet detecting cancer earlier is not synonymous with proving that population-wide screening reduces mortality. Selection, false-positive findings, lead-time bias, and overdiagnosis can alter the apparent benefit of surveillance.
A pancreatic cancer research initiative, the Cancer of the Pancreas Screening (CAPS) programme, described by Dbouk and colleagues in the Journal of Clinical Oncology in 2022, studied surveillance among people at elevated inherited or familial risk. In the combined CAPS1–5 cohort of 1,731 high-risk participants, 26 PDAC cases were diagnosed; 19 were identified within surveillance, and 57.9% of these surveillance-detected cancers were stage I. [8]
In pancreatic cancer research, the report also described substantial survival among surveillance-detected cases, but the observational design does not establish the same causal evidence as random assignment. For pancreatic cancer research, the data are an encouraging signal in selected high-risk populations, not validation of routine screening for every asymptomatic person.
Three biases that early-detection reports must address
- Lead-time bias: Diagnosis happens earlier even if the time of death is unchanged.
- Length-time bias: Slower-growing disease may be disproportionately represented among screen-detected cases.
- Selection bias: People entering intensive surveillance programmes may differ from the general population in risk, resources, or follow-up.
In pancreatic cancer research, these concepts do not mean that the CAPS findings are unimportant. They clarify what additional research is needed to measure net benefit, potential harms, and the right populations for evaluation.
Pancreatic cancer research also investigates circulating tumour DNA, molecular biomarkers, imaging interpretation, and combinations of measurements. A biomarker’s ability to differentiate known cases from healthy controls is only an early stage of validation. Prospective performance in the intended screening population is the harder test.
Finding 9: Laboratory promise still needs clinical proof
For pancreatic cancer research, pancreatic tumours can involve complex interactions among malignant cells, stromal tissue, immune cells, blood vessels, and molecular signalling pathways. Laboratory models investigate these interactions and may identify possible intervention targets. Such models are indispensable for developing hypotheses, but they do not demonstrate effectiveness in humans.
For pancreatic cancer research, the distinction between preclinical evidence and clinical evidence is particularly important when discussing peptides, signalling molecules, or experimental immune approaches. A change in a cell line, an organoid, or an animal tumour is not proof of survival improvement or acceptable safety in people.
The translation pathway
In pancreatic cancer research, researchers may move from mechanistic assays to independent replication, toxicology, early human safety work, and then appropriately controlled trials of clinical outcomes. Each step addresses a different uncertainty. Some candidates fail to reproduce an early result. Others show biological activity but unacceptable toxicity or no meaningful clinical benefit.
Pancreatic cancer research articles should label every claim by evidence stage. Terms such as experimental, preclinical, and investigational are substantive boundaries. They prevent a preliminary observation from being confused with an authorized or validated human intervention.
Immunotherapy is a test case in precision
In pancreatic cancer research, immune-based approaches are active areas of investigation, but pancreatic ductal adenocarcinoma has historically been difficult to treat with immune checkpoint strategies in unselected populations. Certain uncommon molecular subgroups may behave differently. It would be inaccurate to generalize subgroup observations or preclinical immune activation to all tumours.
For pancreatic cancer research, the most reliable claims will emerge from trials that verify a biomarker, specify a comparison, capture meaningful outcomes, and report adverse events. Neither popularity nor laboratory sophistication replaces that requirement.
Side-by-side evidence table
The table below contains results from named publications with distinct patient populations and endpoints. Numbers should be compared within each study’s design. They are not interchangeable rankings of experimental or established clinical strategies.
| Publication | Study population | Verified numerical finding | Evidence boundary |
|---|---|---|---|
| PRODIGE 24/CCTG PA6, 2018 [1] | Postoperative PDAC at 77 France–Canada hospitals | Median OS 54.4 vs 35.0 months | Specific resected-disease population |
| PRODIGE 24 long-term follow-up, 2022 [2] | 493 randomized participants from the same trial | Five-year OS 43.2% vs 31.4% | Updated analysis, not a new independent trial |
| NAPOLI 3, 2023 [3] | 770 participants with metastatic PDAC | Median OS 11.1 vs 9.2 months | Metastatic setting only |
| POLO, 2019 [4, 5] | 154 with germline BRCA-mutated metastatic disease meeting eligibility criteria | Median PFS 7.4 vs 3.8 months | No proven overall-survival advantage in subsequent analysis |
| PREOPANC, long-term 2022 [6] | 246 resectable/borderline-resectable cases | Five-year OS 20.5% vs 6.5% | Specific preoperative sequence comparison |
| Alliance A021501, 2022 [7] | 126 borderline-resectable cases | 18-month OS 66.7% vs 47.3% | Phase 2 arms benchmarked against historical control |
| CAPS1–5, 2022 [8] | 1,731 high-risk surveillance participants | 19 surveillance-detected PDAC cases, 57.9% stage I | Observational, selected high-risk population |
How to read the numbers responsibly
The term median identifies the middle of a survival-time distribution under the study’s estimation method. It does not mean all participants experience the median outcome. A five-year survival estimate represents a different summary and time horizon. Neither should be presented without its starting point and disease setting.
Pancreatic cancer research is also subject to random uncertainty, censoring, missing data, competing risks, and changing standards of care. An apparent difference needs examination of its confidence interval and prespecified endpoint. An association observed in surveillance is not equivalent to an effect demonstrated through random assignment.
Where the next research questions lie
Several research directions could help close current evidence gaps. They include earlier and more accurate disease characterization, biomarkers tested in prospective cohorts, better representation of diverse populations, and endpoints that capture function and quality of life alongside survival. No direction is guaranteed to yield a clinically meaningful improvement.
1. Better prospective validation of detection tools
Blood-based markers, imaging methods, and multivariable risk models need evaluation before diagnoses occur, with documented specificity as well as sensitivity. In a low-prevalence population, even apparently accurate tests may produce many false-positive results. Researchers must consider the consequences of additional procedures and anxiety when evaluating net benefit.
For pancreatic cancer research, a successful detection programme needs more than an impressive case-versus-control classification statistic. It needs evidence about which population benefits, whether outcomes improve, and whether harms are proportionate.
2. Molecularly stratified trial designs
Genomic and tumour-microenvironment characteristics may define relevant subgroups. However, a subgroup from an exploratory analysis may be too small for stable estimates. Prospective protocols, independent validation, and robust biomarker assays reduce the risk of false discoveries.
Pancreatic cancer research should distinguish inherited variants from alterations found only in a tumour, and predictive markers from prognostic markers. A marker associated with disease course is not necessarily evidence that a specific intervention works better in that group.
3. Outcomes meaningful beyond imaging
Tumour measurements and biomarkers are useful intermediate signals, but major trials need prespecified endpoints that matter to participants. Survival, symptom burden, functional outcomes, adverse events, and patient-reported quality of life may each contribute a different dimension of evidence.
For pancreatic cancer research, there is value in publishing negative findings and incomplete results with the same care as favourable outcomes. Selective presentation can make a field seem more advanced than it is and lead readers to confuse experimental excitement with established patient benefit.
4. Research participation and equity
Geography, referral pathways, travel demands, language, age, comorbidity, and socioeconomic factors may influence research participation. A trial involving tertiary centres may not represent every setting in which people receive care. Investigators need to disclose enrolment patterns, attrition, and practical limits to generalization.
Pancreatic cancer research benefits from patient and community engagement in study design and from transparent reporting of who could not participate. This is part of scientific rigor, not merely an administrative diversity statement.
5. Reproducibility and conflicts of interest
Protocols, trial registrations, complete outcome tables, and data-sharing practices help independent teams evaluate claims. Commercial and noncommercial funding sources should be transparently disclosed. No company- or vendor-reported performance data are used as scientific outcome evidence in this article.
Good pancreatic cancer research communication emphasizes what a study directly measured and where interpretation begins. It preserves real progress without turning an exploratory biomarker, a cell experiment, or a subgroup trend into a clinical conclusion.
Frequently asked questions
1. What is one major pancreatic cancer trial with Canadian participation?
The PRODIGE 24/CCTG PA6 randomized trial involved 77 hospitals in France and Canada. The original 2018 publication reported median overall survival of 54.4 versus 35.0 months among studied participants after surgery. Its results relate to a defined postoperative PDAC population, not every case of pancreatic cancer. [1]
2. Has pancreatic cancer research improved survival in metastatic disease?
Some randomized comparisons have demonstrated measurable differences in specific metastatic populations. For example, NAPOLI 3 enrolled 770 participants and reported median overall survival of 11.1 versus 9.2 months in its two studied groups. The result must be interpreted together with eligibility criteria, adverse events, and the trial comparator. [3]
3. What did the POLO trial show about BRCA mutations?
POLO studied 154 participants with germline BRCA1/2-mutated metastatic pancreatic cancer who met specific earlier-treatment criteria. Median progression-free survival was 7.4 versus 3.8 months. Subsequent overall-survival analysis did not establish a significant overall-survival advantage; a PFS finding is not the same as a proven OS benefit. [4, 5]
4. Can pancreatic cancer be detected early through screening?
The CAPS1–5 programme observed promising stage distributions among selected people at high inherited or familial risk: 57.9% of 19 surveillance-detected PDAC cases were stage I. This observational result does not establish a benefit from universal population screening and requires attention to lead-time, selection, and other biases. [8]
5. Do laboratory discoveries mean an experimental peptide or molecule works in humans?
No. A laboratory or animal result can establish a potential mechanism or justify additional investigation, but it does not prove human survival benefit, safety, or clinical effectiveness. Pancreatic cancer research requires appropriately designed human trials with defined comparators and meaningful outcomes before such claims are justified.
References
- Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. New England Journal of Medicine. 2018;379:2395–2406. DOI: 10.1056/NEJMoa1809775. https://www.nejm.org/doi/full/10.1056/NEJMoa1809775
- Conroy T, Castan F, Lopez A, et al. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. JAMA Oncology. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9437831/
- Wainberg ZA, Melisi D, Macarulla T, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3). The Lancet. 2023. https://pubmed.ncbi.nlm.nih.gov/37708904/
- Golan T, Hammel P, Reni M, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. New England Journal of Medicine. 2019;381:317–327. DOI: 10.1056/NEJMoa1903387. https://www.nejm.org/doi/full/10.1056/NEJMoa1903387
- Kindler HL, Hammel P, Reni M, et al. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. Journal of Clinical Oncology. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC10476841/
- Versteijne E, van Dam JL, Suker M, et al. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial. Journal of Clinical Oncology. 2022. https://pubmed.ncbi.nlm.nih.gov/35084987/
- Katz MHG, Shi Q, Meyers JP, et al. Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial. JAMA Oncology. 2022. https://pubmed.ncbi.nlm.nih.gov/35834226/
- Dbouk M, Katona BW, Brand RE, et al. The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival. Journal of Clinical Oncology. 2022. https://pubmed.ncbi.nlm.nih.gov/35704792/
- World Pancreatic Cancer Coalition. World Pancreatic Cancer Day and Awareness Month. 2026. https://www.worldpancreaticcancercoalition.org/our-impact/
For laboratory research use only. Not for human consumption.
